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Abstract
The HIV-1 primary transcript undergoes a complex splicing process by which more than 40 different spliced RNAs are
generated. One of the factors contributing to HIV-1 splicing complexity is the multiplicity of 39 splice sites (3’ss) used for
generation of rev RNAs, with two 3’ss, A4a and A4b, being most commonly used, a third site, A4c, used less frequently, and
two additional sites, A4d and A4e, reported in only two and one isolates, respectively. HIV-1 splicing has been analyzed
mostly in subtype B isolates, and data on other group M clades are lacking. Here we examine splice site usage in three
primary isolates of subtype C, the most prevalent clade in the HIV-1 pandemic, by using an in vitro infection assay of
peripheral blood mononuclear cells. Viral spliced RNAs were identified by RT-PCR amplification using a fluorescently-labeled
primer and software analyses and by cloning and sequencing the amplified products. The results revealed that splice site
usage for generation of rev transcripts in subtype C differs from that reported for subtype B, with most rev RNAs using two
previously unreported 3’ss, one located 7 nucleotides upstream of 3’ss A4a, designated A4f, preferentially used by two
isolates, and another located 14 nucleotides upstream of 3’ss A4c, designated A4g, preferentially used by the third isolate. A
new 59 splice site, designated D2a, was also identified in one virus. Usage of the newly identified splice sites is consistent
with sequence features commonly found in subtype C viruses. These results show that splice site usage may differ between
HIV-1 subtypes.
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Introduction
All HIV-1 RNAs are transcribed from a single promoter at the
59 long terminal repeat, and their relative expression is regulated
through alternative splicing. According to the splicing events used
for their generation, HIV-1 RNAs can be assigned to three
categories: 1) unspliced RNA, coding for Gag and Pol; 2) singly
spliced (SS) transcripts, which code for Env, Vpu, Vif, Vpr, and a
truncated form of Tat; and 3) doubly spliced (DS) transcripts,
which code for Tat, Rev, Nef, and Vpr. Four 59 splice sites (5’ss)
and nine 39 splice sites (3’ss) (including three 3’ss used by rev RNAs,
A4a, A4b, and A4c) are commonly used by HIV-1, generating
more than 40 different transcripts [1,2] (Fig. 1). Additionally,
multiple other splice sites are used infrequently [1,3–10]. Most
HIV-1 splice sites exhibit suboptimal efficiencies [11–15], which
allow for regulation of their relative usage by the action of cellular
splice regulatory factors binding to splice enhancer and suppressor
elements in the HIV-1 genome [16].
Previous studies on HIV-1 splicing have been done almost
exclusively using subtype B viruses, usually T-cell line-adapted
isolates. To our knowledge, non-subtype B viruses reported to be
analyzed for splicing patterns are limited to two group O viruses
[8,17]. Here we analyze splice site usage by primary isolates of
subtype C, the most prevalent clade in the HIV-1 pandemic [18],
using an in vitro infection assay of peripheral blood mononuclear
cells (PBMCs).
Materials and Methods
Three subtype C primary isolates, X1702-3, X1936, and
X2363-2 [19,20], were used for infection of PBMCs, obtained
from healthy donors, who gave their written informed consent. For
each isolate, infection assays were done in triplicate using PBMCs
from three different donors. The subtype B isolate NL4-3 was used
as control in one of the assays. PBMCs were prestimulated with
phytohemagglutinin and interleukin-2 for three days and exposed
to virus at a multiplicity of infection of 0.1 50% tissue culture
infectious dose (TCID50) per cell for 2 h, followed by two washes
with phosphate-buffered saline. Cells were collected on days 1, 2,
3, 4, and 7 postinfection and total RNA was extracted. HIV-1
splicing patterns were analyzed through RT-PCR followed by
nested PCR, using primers recognizing sequences in the outermost
exons common to either all DS or SS HIV-1 RNAs, yielding
amplified products of different sizes according to the splice sites
used for generation of the transcripts. Reagents and PCR
conditions were similar to those described previously [10], except
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30574that in the nested PCR 15 cycles were used, the sense primer was
US22 [CTCGACGCAGGACTCGGCTTGC, HXB2 nucleo-
tides (nt) 685–706], and for DS RNAs the antisense primer was
TRN-AS (CGGTGGTAGCTGAARAGGCACAG, HXB2 nt
8511–8533). US22 was 59-labeled with VIC fluorophore, which
allowed for analysis of the amplified products electrophoresed in
an automated sequencer by using GeneMapper software program
(Applied Biosystems, Carlsbad, CA), which can accurately
determine sizes of PCR products by running a size standard
labeled with a different fluorophore in the same capillary and
quantify them by measuring peak areas. Identification of PCR
products with sizes different from those expected by the use of
known splice sites was done through TA cloning and sequencing of
the amplified products.
Results
GeneMapper analyses revealed that most peaks derived from
spliced transcripts in the three subtype C isolates corresponded to
sizes expected for HIV-1 transcripts using previously reported
splice sites. However in all three viruses, peaks with unexpected
sizes were detected among DS transcripts (Fig. 2). In X1702-3 and
X1936, three peaks were 7 nt longer than predicted for rev
transcripts using A4a (1.4a.7, 1.3.4a.7, and 1.2.3.4a.7). Interest-
ingly, in both viruses, transcripts using A4a and A4b, the most
common 3’ss used for rev RNA generation in subtype B isolates,
were not detected. In X2363-2, peaks with sizes 14 nt longer than
those corresponding to rev transcripts using A4c (1.4c.7, 1.2.4c.7,
and 1.3.4c.7) were detected. In NL4-3, all peaks corresponded to
sizes expected from the usage of known splice sites (Fig. 2j).
Since most peaks with unexpected sizes were close to those
predicted for known rev transcripts, and those corresponding to
RNAs using 3’ss A4a and A4b were either undetected or relatively
weak, we suspected that the unidentified peaks corresponded to rev
transcripts using previously unreported splice sites. To examine
this possibility, nested PCRs using the antisense primer TatRev-
AS (GCTTCTTCCTGCCATAGGAGATGC, HXB2 nt 5961–
5984) recognizing a sequence downstream of A4b and upstream of
A5, able to amplify all known rev transcripts, in addition to tat and
vpr (but not nef) RNAs, were done using RT-PCR products derived
from DS transcripts from PBMCs collected on day 2 postinfection.
In all three subtype C viruses, the analyses of sequences of the
cloned products revealed the preferential usage of previously
unreported 3’ss for generation of rev RNAs located at positions in
the HIV-1 genome consistent with peaks detected with Gene-
Mapper (Fig. 3, Table 1). In X1702-3 and X1936, rev RNAs
preferentially used a 3’ss at HXB2 position 5948, 7 nt upstream of
A4a, which was designated A4f (named consecutively after A4d,
identified in one isolate of subtype B and one of group O, and A4e,
identified in a group O virus [8]). A4f was used in 20 (90.9%) of 22
rev clones in X1702-3 and in 18 (94.7%) of 19 rev clones in X1936,
with the remaining rev transcripts using A4c. In X2363-2, all 12
analyzed rev clones used a 3’ss at HXB2 position 5923, 14 nt
upstream of A4c, which was designated A4g (splicing at this site
does not create a new open reading frame, since there is no AUG
between it and the Rev initiation codon). One clone of X2363-2
contained three noncoding exons upstream of A4g, corresponding
to exon 1, a second exon 91 nt long using 3’ss A1 and a newly
identified 5’ss at HXB2 position 5003, 41 nt downstream of 5’ss
D2 (which was designated D2a), and exon 3. The proportion of rev
transcripts using A4f in X1702-3 and X1936 and A4g in X2363,
as determined by clone sequencing, was generally consistent with
quantification of peak areas in GeneMapper analyses (Table 2).
Sequencing of clones of PCR products derived from SS RNAs also
revealed the usage of A4f in X1702-3 and X1936 and of A4g in
X2363 (results not shown).
We examined sequence features surrounding the newly
identified splice sites that could explain different splice site usage
by the subtype C isolates, compared to subtype B (Fig. 4). The
usual elements of the metazoan 3’ss include an AG at the 39 end
of the intron, a branch point site (BPS), usually 18–40 nt
upstream of the AG, whose sequence is weakly conserved among
mammalians (in humans, the consensus sequence is simply
yUnAy, where the underline denotes the branch point, and
lowercase pyrimidines are less conserved than the uppercase U
and A [21,22]), and a polypirimidine tract (PPT) downstream of
the BPS. All three subtype C isolates have the AG and a PPT
with 8 pyrimidines (UUUGUUUUC) (interrupted by a purine,
similarly to all HIV-1 3’ss, which are suboptimal due to
interspersed purines [11–14]) upstream of A4f. All also have an
AG 59-adjacent to A4g, but only X2363-2 has a sequence with 5
pyrimidines (UCUUGC) just upstream of this AG and one with 7
pyrimidines (CUCCUUGU) 34 to 27 nt upstream of A4g, which
may contribute to preferential usage of this site in X2363-2 but
not in X1702-3 and X1936. Among full-length HIV-1 genomes
[23], sequence features consistent with potential usage of A4f and
A4g are common in subtype C viruses, but are rare in other
subtypes. Thus, among subtype C viruses, the AG adjacent to A4f
Figure 1. Schematic representation of HIV-1 splicing. Open reading frames are shown as open boxes and exons as black bars. Exons are
named as previously [1,2]. All spliced transcripts incorporate exon 1. Optionally, noncoding exons 2 or 3 or both can be incorporated into tat, rev, nef,
or env transcripts, and exon 2 into vpr transcripts. Proteins encoded in spliced RNAs are indicated on the right of the 39 exon.
doi:10.1371/journal.pone.0030574.g001
rev Splicing in HIV-1 Subtype C
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97% viruses, while the AG adjacent to A4g is found in 87%
sequences, with a PPT of 5 pyrimidines just upstream of this AG
in 3%, and one of 5 or 6 consecutive pyrimidines within 40 nt
upstream of A4g in 60%. In a previous study, four branch points
used for generation of rev transcripts were identified in the
subtype B isolate NL4-3, two for splicing at 3’ss A4a and A4b and
two for splicing at 3’ss A4c [14] (Fig. 4a). Three of these branch
points were also shown to be used by the subtype B isolate SF2
[8]. One of these BPS, located 20 nt upstream of A4f, could
Figure 2. GeneMapper analyses of DS RNAs expressed by three HIV-1 subtype C primary isolates in PBMCs. Green peaks represent PCR
products and orange peaks represent size standards. Size of PCR product, encoded gene, and exon composition (named as in previous studies [1,2])
predicted according to the size of the PCR product are shown on top or on the side of each peak. Peaks whose sizes do not match HIV-1 transcripts
using previously reported splice sites are marked with interrogation signs. For each subtype C virus, three GeneMapper analyses are shown,
corresponding to infections using PBMCs from three different donors.
doi:10.1371/journal.pone.0030574.g002
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the conserved BPS motif UnA at this site [21,22]. By contrast, in
X2363-2 a C is found at position -2 from the potential branch
point which may explain the infrequent use of A4f in this isolate.
With regard to A4g, potential BPS are those identified in NL4-3
and SF2 [8,14], used for splicing at A4c, located 10 and 16 nt,
respectively, upstream of A4g. At both sites, the sequence in
X2363-2 contains the UnA motif, whereas X1702-3 and X1936
have Cs at position -2 from the branch sites identified in subtype
B viruses. If the PPT located 34-27 nt upstream of A4g is the one
used for splicing at this site, there is one possible BPS just
upstream of this PPT with sequence ACCUAAA, which has 4
consecutive nt complementary to U2 snRNP (underlined)
(Fig. 4a), whose base-pairing to the BPS is an important step in
mRNA splicing [24,25]. The sequence analyses therefore may
explain differential 3’ss usage for rev RNA generation between
subtype B and subtype C viruses, and, within subtype C, between
different isolates, and suggest the locations of potential BPS used
for newly identified 3’ss in subtype C viruses. However BPS
locations need to be experimentally determined, as multiple
factors in addition to the weakly conserved BPS sequence,
including PPT sequence, length, and proximity to the BPS [26–
Figure 3. Sequence electropherograms of splice junctions newly identified in subtype C isolates. Splice junctions are shown as vertical
lines. 59 and 39 splice sites involved in splicing, named as in previous studies [1,2] and in this study (see main text), are signaled, with nucleotide
positions in the HXB2 genome in parentheses. Nearby splice sites are also indicated.
doi:10.1371/journal.pone.0030574.g003
Table 1. Exon composition of clones derived from DS rev and tat RNAs expressed by three subtype C isolates*.
rev tat
Isolate 1.4f 1.3.4f 1.2.3.4f 1.4c 1.4g 1.2.4g 1.3.4g 1.2a.3.4g 1.4 Total
X1702-3 15 5 2 1 23
X1936 11 5 2 1 2 21
X2363-2 9 1 1 1 12
Exons 1, 2, 3, 4c, and 4 are named as in previous studies [1,2]. Exons 4f and 4g designate those using newly identified 3’ss A4f and A4g, respectively, and exon 2a
designates that using 3’ss A1 and newly identified 5’ss D2a (see main text). All transcripts are assumed to include exon 7 through splicing from 5’ss D4 to 3’ss A7.
However this splice junction was not sequenced, since the antisense PCR primer anneals upstream of D4. nef RNAs were not amplified because the antisense PCR primer
recognizes a sequence upstream of 3’ss A5.
doi:10.1371/journal.pone.0030574.t001
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elements [16,30], may influence BPS selection.
With regard to D2a, occasionally used in X2363-2, the
sequence is AAG|GUAGUA (the vertical line indicates the
exon-intron border), which has 5 potential base-pairings with U1
snRNA (underlined) (Fig. 4b). Previous studies have shown that the
strength of a 5’ss correlates with the stability of its interaction with
U1 sRNA [31,32], which for D2a may be similar to D2, which
also has 5 potential base-pairings with U1 snRNA. The D2a
sequence in X2363-2 coincides with the consensus of most
subtypes, except B and H. The subtype B consensus is
AAA|GUAGUA, whose predictable weak interaction with U1
snRNA, with only 4 potential discontinuous base-pairings
(underlined), may preclude its usage as 5’ss.
Discussion
This study is the first to analyze splice site usage by viruses of
HIV-1 subtype C, which is the most prevalent clade in the HIV-1
pandemic, estimated to represent around 48% global infections
[18]. The most notable finding is that subtype C primary isolates,
in contrast to subtype B viruses, rarely use 3’ss A4a and A4b for
generation of rev transcripts, and, instead, they preferentially use
two previously unreported 3’ss, designated A4f and A4g, located,
respectively, 7 nt upstream of A4a and 14 nt upstream of A4c.
Usage of these splice sites is consistent with sequence features
commonly found in viruses of subtype C, which frequently contain
an AG dinucleotide at the intron’s end adjacent to the newly
identified splice sites, as well as upstream PPT and sequences with
potential to be used as branch points. The infrequent usage of A4a
and A4b in subtype C viruses may derive from the linear scanning
mechanism for 3’ss recognition [33], whereby the nt after the first
AG downstream of the BPS is preferentially selected as splice site.
Although the mammalian BPS sequence is highly variable
[21,22,25], it contains two conserved positions, corresponding to
the A at the branch site and the U two nt upstream of it
[21,22,34]. In two isolates, X1702 and X1936, a potential BPS
would be one previously identified in the subtype B isolates NL4-3
and SF2 [8,14], used for splicing at A4a and A4b, located 20 nt
upstream of A4f (Fig. 4a). Although the sequence in X1702 and
X1936 at this BPS differs from that of NL4-3 in two nt, the
conserved UnA motif is maintained, and at position +1 from the
branch site there is one additional potential G-C base-pairing with
U2 snRNP, whose complementarity to the BPS has been shown to
correlate positively with splicing efficiency [24,35]. The first AG
encountered downstream of this BPS in X1702-3 and X1936 is
that immediately upstream of A4f, and this would explain the
preferential usage of this splice site over A4a and A4b in these
isolates. In the third subtype C isolate, X2363-2, failure to use A4f
may derive from sequence changes at the previously mentioned
Table 2. Relative expression of rev RNAs in subtype C viruses according to peak areas in GeneMapper analyses.
Isolate PCR product size Exon composition % total rev RNA peak area % rev clones
X1702-3
1 305 1.4f.7 70.3 68.2
316 1.4c.7 7.1 9.1
379
2 1.3.4f.7 18.0 22.7
390 1.2.4c.7 3.9 -
428 1.2.3.4f.7 0.8 -
X1936
1 305 1.4f.7 52.2 57.9
316 1.4c.7 8.6 5.3
379
2 1.3.4f.7 27.4 26.3
390 1.2.4c.7 9.0 -
428 1.2.3.4f.7 2.7 10.5
X2363-2 299 1.4a.7 2.6 -
305 1.4f.7 0.8 -
331 1.4g.7 50.1 75.0
367
3 1.2.4c.7 9.1 -
380
2 1.2.4g.7 6.7 8.3
390 1.3.4c.7 0.7 -
404 1.3.4g.7 19.5 8.3
421 1.2a.4g.7 5.8 -
440 1.2.3.4c.7 1.6 -
454 1.2.3.4g.7 2.0 -
494 1.2a.3.4g.7 1.1 8.3
Results correspond to peaks shown in Fig. 2, and are shown as % of individual peak areas relative to the sum of peak areas of all rev RNA-derived products. Percentages
at the column on the right correspond to the cloned and sequenced rev RNA-derived amplicons (Table 1).
1A small 331 nt peak, coincident with that of 1.4g.7 rev RNA, was seen in X1702-3 and X1936 (Fig. 2). However, nested PCR using an antisense primer specific for rev, tat
and vpr RNAs failed to detect 1.4g.7 rev RNA in these isolates.
2Nested PCR with primers recognizing exons 2 and 3 allowed to confirm that these products, only 1 nt longer in X1702-3 and X1936 than in X2363-2, correspond to
1.3.4f.7 in the first two viruses and to 1.2.4g.7 in the third one.
3The 367 nt peak seen in X2363-2 may correspond to both 1.2.4c.7 and 1.3.4b.7 rev RNAs. Nested PCR using primers recognizing exons 2 and 3 allowed to determine
that this peak corresponds to 1.2.4c.7.
doi:10.1371/journal.pone.0030574.t002
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identified in subtype B viruses. The sequence at a second BPS
previously identified in NL4-3 for splicing at A4a and A4b, located
6 nt downstream of the previous one, also may fail to function as
BPS in X2363-2, because the A used as BPS is substituted for U
(Fig. 4a). Although the sequence at a potential branch site may
determine its use by the splicing machinery, it is important to note,
as stated above, that it is only one factor among others, which also
include the PPT sequence, length and proximity to the BPS [26–
29] and the presence of nearby splice enhancer and suppressor
elements [16,30], contributing to the selection of the BPS, whose
actual location needs to be determined experimentally.
The reason A4c is not used more frequently in the analyzed
subtype C viruses may derive from weak PPT, which contain 3 or
4 purines interspersed among 8 or 9 pyrimidines. These sequences,
in spite of lacking runs of pyrimidines longer than 3 nt, could still
act as functional PPT, in accordance with a previous study
showing that a stretch of alternating purines and pyrimidines can
promote branch point selection [29]. The close proximity of this
PPT to the downstream AG [29] and the presence of an exonic
splice enhancer (GAR ESE) at exon 5 [36] could also contribute to
render this weak PPT functional. In X2363-2, the scanning
mechanism selecting A4g as 3’ss would also explain the infrequent
usage of A4c and other downstream 3’ss.
Occasional use of a new 5’ss, designated D2a, located 41 nt
downstream of D2, was also observed in one subtype C isolate,
X2363-2. Usage of D2a is also consistent with sequences present in
this isolate and in most subtype C viruses, which have greater
complementarity with U1 snRNA at this site relative to subtype B
viruses. In addition, the usage of D2a as an alternative to D2 in
subtype C may be favored by the fact that D2 is a suboptimal 5’ss
[15]. Its less frequent usage relative to D2 may derive from the
scanning mechanism proposed for recognition of the 5’ss, whereby
among several consecutive potential sites, the 59-most site is usually
selected [37].
With the newly identified sites, seven 3’ss have been reported to
be used in HIV-1 for rev RNA generation, which, in addition to the
commonly used A4a, A4b, and A4c, also include A4d, located 5 nt
upstream of A4a, reported in the subtype B isolate SF2 and the
group O virus ANT70C [8] [and also preferentially used by one
additional subtype B primary isolate studied by us (unpublished
data)], and A4e, located 1 nt upstream of A4a, reported in
ANT70C [8] (and, according to the presence of an intronic AG
dinucleotide adjacent to the A4e site, also predicted to be used by
most subtype F and CRF02_AG viruses). Such multiplicity of 3’ss
used for rev RNA generation may derive from the facts that rev 39
splice sites are located in the first coding exon of Tat, which is one
of the most variable HIV-1 proteins [38], and that HIV-1
replication is absolutely dependent on Rev, whose absence cannot
be compensated by viruses from other infected cells, as occurs with
Tat, which can be secreted extracellularly and activate HIV-1
transcription in neighboring cells [39].
Previously reported in vitro biological features which may differ
between HIV-1 subtypes include the response of the transcrip-
tional promoter to tumor necrosis factor-alpha [40–44], replicative
capacity [45,46], use of coreceptors [47–51], and activity of
Figure 4. Intronic and exonic sequences surrounding newly identified splice sites in three subtype C isolates. Sequences are aligned
with consensuses of subtypes B and C. (a) Sequences surrounding 3’ss A4f and A4g. AG dinucleotides in the intron ends adjacent to splice sites are in
bold type. Polypyrimidine tracts potentially used for splicing at A4f and A4g are boxed. The sequences of subtype B NL4-3 and SF2 isolates are on
bottom with branch sites previously identified for rev RNA splicing [8,14] underlined. Nucleotides in the subtype C isolates and in the consensus
subtype C sequence potentially used as branch points for splicing at A4f and A4g (see main text) are indicated with arrows. (b) Sequences
surrounding 5’ss D2 and D2a. Exon-intron borders are signaled with vertical lines. Highly conserved GU dinucleotides at intron ends adjacent to the
5’ss are in bold type. Nucleotides at splice sites potentially pairing with U1 snRNA are underlined.
doi:10.1371/journal.pone.0030574.g004
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biological feature in which HIV-1 subtypes may differ, which is the
usage of RNA splice sites.
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